Finance

Lists
Why is 2359 down 2.22%?
Dive Deeper
2359:HKG
WuXi AppTec Ord Shs H
HK$176.00
-2.22%
(-4.00) 1D
Nov 3, 4:08:07 PM GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 2359...
Open
HK$181.10
High
HK$181.10
Low
HK$172.40
Mkt. cap
488.03B
Avg. vol.
6.07M
Volume
8.01M
Dividend
1.36%
Quarterly dividend
HK$0.60
Ex-dividend date
Sep 4, 2026
P/E ratio
21.41
52-wk high
HK$219.20
52-wk low
HK$96.70
EPS
HK$8.22
No. of employees
36K
Open
HK$181.10
High
HK$181.10
Low
HK$172.40
Mkt. cap
488.03B
Avg. vol.
6.07M
Volume
8.01M
Dividend
1.36%
Quarterly dividend
HK$0.60
Ex-dividend date
Sep 4, 2026
P/E ratio
21.41
52-wk high
HK$219.20
52-wk low
HK$96.70
EPS
HK$8.22
No. of employees
36K
News stories
From web sources and news partners
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe. Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
About WuXi AppTec Ord Shs H
CEOSteve Yang | Ge Li
Employees35.6K
FoundedDec 1, 2000
Headquarters-
SectorHealth care
Last report
Oct 26, 2026
Fiscal period
Q3 2026
CNÂ¥1.99 / CNÂ¥1.91
+4.43%beat
Revenue / Est. (CNY)
16.64B / 15.67B
+6.20%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
10.97B
12.44B
16.46B
16.64B
Cost of goods sold
4.91B
6.17B
-
7.57B
Cost of revenue
4.91B
6.17B
-
7.57B
Research and development expenses
236.94M
266.96M
-
318.39M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
853.67M
891.80M
-
1.25B
Operating expense
1.26B
1.22B
-
1.58B
Total operating expenses
6.17B
7.39B
-
9.15B
Operating income
4.80B
5.04B
-
7.49B
Other non operating income
281.37M
-266.37M
-
-959.42M
EBT including unusual items
6.75B
5.61B
-
10.53B
EBT excluding unusual items
6.95B
5.19B
-
11.10B
Income tax expense
1.09B
936.77M
-
2.15B
Effective tax rate
16.12%
16.71%
-
20.44%
Other operating expenses
25.84M
726.05K
-
-44.12M
Net income
7.08B
4.65B
-
8.28B
Net profit margin
64.49%
37.40%
-
49.73%
Earnings per share
1.42
1.57
2.20
1.99
Interest and investment income
1.87B
439.82M
-
4.00B
Interest expense
-
-30.95M
-
-62.24M
Net interest expenses
1.87B
408.87M
-
3.94B
Depreciation and amortization charges
-
-
-
-
EBITDA
5.61B
5.85B
-
8.29B
Gain or loss from assets sale
218.40M
-
-
-14.60M
Upcoming events
AI content may include mistakes. Learn more
Google apps